Emiel van der Kouwe
YOU?
Author Swipe
View article: Supplementary Data from Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders
Supplementary Data from Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders Open
Supplementary Data containing the statistical analysis plan, Supplemental Figures 1-6 and Supplemental Tables 1 and 2
View article: Data from Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders
Data from Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders Open
Personalized medicine aims to match the right drug with the right patient by using specific features of the individual patient's tumor. However, current strategies of personalized therapy matching provide treatment opportunities for less t…
View article: Supplementary Data from Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders
Supplementary Data from Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders Open
Supplementary Data containing the statistical analysis plan, Supplemental Figures 1-6 and Supplemental Tables 1 and 2
View article: Data from Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders
Data from Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders Open
Personalized medicine aims to match the right drug with the right patient by using specific features of the individual patient's tumor. However, current strategies of personalized therapy matching provide treatment opportunities for less t…
View article: Data from <i>IL2RA</i> Promotes Aggressiveness and Stem Cell–Related Properties of Acute Myeloid Leukemia
Data from <i>IL2RA</i> Promotes Aggressiveness and Stem Cell–Related Properties of Acute Myeloid Leukemia Open
Overexpression of IL2RA, which encodes the alpha chain of the IL2 receptor, is associated with chemotherapy resistance and poor outcome in acute myeloid leukemia (AML). The clinical potential of anti-IL2RA therapy is, therefore, being expl…
View article: Supplemental table 4 from <i>IL2RA</i> Promotes Aggressiveness and Stem Cell–Related Properties of Acute Myeloid Leukemia
Supplemental table 4 from <i>IL2RA</i> Promotes Aggressiveness and Stem Cell–Related Properties of Acute Myeloid Leukemia Open
Supplemental Table 4 shows the effect of hIL2RA antibody on the relative abundance of different progenitor populations among healthy human BM cells.
View article: Data from <i>IL2RA</i> Promotes Aggressiveness and Stem Cell–Related Properties of Acute Myeloid Leukemia
Data from <i>IL2RA</i> Promotes Aggressiveness and Stem Cell–Related Properties of Acute Myeloid Leukemia Open
Overexpression of IL2RA, which encodes the alpha chain of the IL2 receptor, is associated with chemotherapy resistance and poor outcome in acute myeloid leukemia (AML). The clinical potential of anti-IL2RA therapy is, therefore, being expl…
View article: Supplemental information from <i>IL2RA</i> Promotes Aggressiveness and Stem Cell–Related Properties of Acute Myeloid Leukemia
Supplemental information from <i>IL2RA</i> Promotes Aggressiveness and Stem Cell–Related Properties of Acute Myeloid Leukemia Open
Supplemental information shows Supplemental methods, Supplemental Table 1, 3, Supplemental Figure Legends, and Supplemental Figures 1 to 8.
View article: Supplemental table 2 from <i>IL2RA</i> Promotes Aggressiveness and Stem Cell–Related Properties of Acute Myeloid Leukemia
Supplemental table 2 from <i>IL2RA</i> Promotes Aggressiveness and Stem Cell–Related Properties of Acute Myeloid Leukemia Open
Supplemental Table 2 shows genes whose expression correlated (Rho >0.4 or <-0.4) with that of IL2RA in 177 AML, and pathways enriched among genes whose expression correlated with that of IL2RA in the TCGA_LAML data set (Metacore).
View article: Supplemental table 2 from <i>IL2RA</i> Promotes Aggressiveness and Stem Cell–Related Properties of Acute Myeloid Leukemia
Supplemental table 2 from <i>IL2RA</i> Promotes Aggressiveness and Stem Cell–Related Properties of Acute Myeloid Leukemia Open
Supplemental Table 2 shows genes whose expression correlated (Rho >0.4 or <-0.4) with that of IL2RA in 177 AML, and pathways enriched among genes whose expression correlated with that of IL2RA in the TCGA_LAML data set (Metacore).
View article: Supplemental information from <i>IL2RA</i> Promotes Aggressiveness and Stem Cell–Related Properties of Acute Myeloid Leukemia
Supplemental information from <i>IL2RA</i> Promotes Aggressiveness and Stem Cell–Related Properties of Acute Myeloid Leukemia Open
Supplemental information shows Supplemental methods, Supplemental Table 1, 3, Supplemental Figure Legends, and Supplemental Figures 1 to 8.
View article: Supplemental table 4 from <i>IL2RA</i> Promotes Aggressiveness and Stem Cell–Related Properties of Acute Myeloid Leukemia
Supplemental table 4 from <i>IL2RA</i> Promotes Aggressiveness and Stem Cell–Related Properties of Acute Myeloid Leukemia Open
Supplemental Table 4 shows the effect of hIL2RA antibody on the relative abundance of different progenitor populations among healthy human BM cells.
View article: Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders
Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders Open
Personalized medicine aims to match the right drug with the right patient by using specific features of the individual patient's tumor. However, current strategies of personalized therapy matching provide treatment opportunities for less t…
View article: Core-binding factor leukemia hijacks the T-cell–prone PU.1 antisense promoter
Core-binding factor leukemia hijacks the T-cell–prone PU.1 antisense promoter Open
The blood system serves as a key model for cell differentiation and cancer. It is orchestrated by precise spatiotemporal expression of crucial transcription factors. One of the key master regulators in the hematopoietic systems is PU.1. Re…
View article: Myeloid lncRNA <i>LOUP</i> mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML
Myeloid lncRNA <i>LOUP</i> mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML Open
The mechanism underlying cell type-specific gene induction conferred by ubiquitous transcription factors as well as disruptions caused by their chimeric derivatives in leukemia is not well understood. Here, we investigate whether RNAs coor…
View article: Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia
Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia Open
International audience
View article: Myeloid lncRNA<i>LOUP</i>Mediates Opposing Regulatory Effects of RUNX1 and RUNX1-ETO in t(8;21) AML
Myeloid lncRNA<i>LOUP</i>Mediates Opposing Regulatory Effects of RUNX1 and RUNX1-ETO in t(8;21) AML Open
The mechanism underlying cell type-specific gene induction conferred by ubiquitous transcription factors as well as disruptions caused by their chimeric derivatives in leukemia is not well understood. Here we investigate whether RNAs coord…
View article: RUNX1-ETO: Attacking the Epigenome for Genomic Instable Leukemia
RUNX1-ETO: Attacking the Epigenome for Genomic Instable Leukemia Open
Oncogenic fusion protein RUNX1-ETO is the product of the t(8;21) translocation, responsible for the most common cytogenetic subtype of acute myeloid leukemia. RUNX1, a critical transcription factor in hematopoietic development, is fused wi…